Physician profile
Steven C Hill
NPI 1316976764
$9,010.55
in general payments reported to CMS, 2019-2025
39 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $1,270 · 2021: $1,452 · 2022: $1,387 · 2023: $793 · 2024: $1,089 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.36 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,296.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $869.09 | 2019-2025 | Jardiance |
| Pfizer INC. | $787.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $511.46 | 2019-2023 | Camzyos |
| Lilly USA, LLC | $506.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $402.53 | 2019-2024 | |
| Glaxosmithkline, LLC. | $395.56 | 2019-2022 | |
| Novo Nordisk INC | $380.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $363.28 | 2019-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $335.19 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $323.45 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.06 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $272.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $269.94 | 2019-2022 | |
| Amgen INC. | $260.90 | 2019-2024 | Evenity, Prolia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.